Structural perspectives on adenosine to inosine RNA editing by ADARs.
ADAR
MT: RNA and epigenetic editing Special Issue
SDRE
adenosine
adenosine deaminase acting on RNA
inosine
nucleic acid therapeutics
site-directed RNA editing
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
21
8
2024
Statut:
epublish
Résumé
Adenosine deaminases acting on RNA (ADARs) are enzymes that catalyze the hydrolytic deamination of adenosine to inosine. The editing feature of ADARs has garnered much attention as a therapeutic tool to repurpose ADARs to correct disease-causing mutations at the mRNA level in a technique called site-directed RNA editing (SDRE). Administering a short guide RNA oligonucleotide that hybridizes to a mutant sequence forms the requisite dsRNA substrate, directing ADARs to edit the desired adenosine. However, much is still unknown about ADARs' selectivity and sequence-specific effects on editing. Atomic-resolution structures can help provide additional insight to ADARs' selectivity and lead to novel guide RNA designs. Indeed, recent structures of ADAR domains have expanded our understanding on RNA binding and the base-flipping catalytic mechanism. These efforts have enabled the rational design of improved ADAR guide strands and advanced the therapeutic potential of the SDRE approach. While no full-length structure of any ADAR is known, this review presents an exposition of the structural basis for function of the different ADAR domains, focusing on human ADAR2. Key insights are extrapolated to human ADAR1, which is of substantial interest because of its widespread expression in most human tissues.
Identifiants
pubmed: 39165563
doi: 10.1016/j.omtn.2024.102284
pii: S2162-2531(24)00171-9
pmc: PMC11334849
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
102284Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
There authors declare no competing interests.